



International Journal of Herbal Medicine

Available online at www.florajournal.com



E-ISSN: 2321-2187
P-ISSN: 2394-0514
IJHM 2015; 3 (1): 10-27
Received: 08-04-2015
Accepted: 10-05-2015

Amal K. Maji
Ulysses Research Foundation,
125, Rash Behari Avenue,
Kolkata 700 029, West Bengal,
India.

Pratim Banerji
Ulysses Research Foundation,
125, Rash Behari Avenue,
Kolkata 700 029, West Bengal,
India.

Chelidonium majus L. (Greater celandine) – A Review on its Phytochemical and Therapeutic Perspectives

Amal K. Maji, Pratim Banerji

Abstract

Chelidonium majus L. (Papaveraceae) is a medicinal herb used in various traditional systems of medicine to treat ulcer, cancer, oral infection, liver disorders, chronic bronchitis, asthma, etc. Different parts of this plant contain numerous therapeutically important alkaloidal constituents such as chelidonine, chelerythrine, sanguinarine, berberine and so on. The plant and its active compounds exhibit a wide range of pharmacological activities. The plant has long history of therapeutic use in medicines without any toxic effect. Today it is one of the important components of some pharmaceutical preparations. Consumption of *C. majus* preparations possesses toxic effects on the liver although the effect becomes controversial with its hepatoprotective effect. Numerous active constituents of *C. majus* interact with various drug metabolizing enzymes that mimic possible interactions of this herb with the conventional drugs. This review provides detailed phytochemical, pharmacological and toxicological information of *C. majus* along with mechanisms of action of its various active compounds on different aspects of pharmacology. This review also highlights plausible drug interaction of its various active compounds and the future prospect of this herb.

Keywords: *C. majus*, phytochemicals, pharmacology, toxicity and drug interactions.

1. Introduction


Chelidonium majus (Papaveraceae) is a well-known medicinal herb distributed in Europe, Asia, and Northern Africa and is widely used against various diseases in European countries and Chinese herbal medicines [1]. It has many common names such as celandine, greater celandine, celandine poppy, elon-wort, felonwort, rock poppy, swallow-wort and tetter-wort [2]. Recently, the extract of *C. majus* was shown to be safe for the use in veterinary and human phyto-preparations [3]. In various complementary and alternative medicine (CAM) systems including homeopathy, different parts of this plant are used to treat gastric ulcer, gastric cancer, oral infection, liver diseases, general pain and various skin disorders [4]. Extracts of leaves, flower and root are internally used to stimulate the production of bile and pancreatic digestive enzymes [5]. Because of choleric and spasmolytic properties, *C. majus* is widely used for the treatment of biliary disorders, dyspepsia, and irritable bowel syndrome [6]. In Chinese herbal medicine, it is used to treat whooping cough, blood stasis, chronic bronchitis, asthma, jaundice, gallstones and gallbladder pains and to promote diuresis in oedema and ascites [2, 7]. In homeopathic medicine, ultra-high dilutions (potencies) of *C. majus* extract are reputedly used against different forms of liver disorders including liver cancer [8]. Phytochemical analysis revealed the presence of numerous active constituents such as chelidonine, chelerythrine, sanguinarine, berberine, protopine, allocryptopine, coptisine and so on. Both, crude extract and purified constituents of *C. majus* exhibited a wide variety of pharmacological activities (anti-inflammatory, antimicrobial, immunomodulatory, anticancer, hepatoprotective, analgesic etc.) [7]. Some review articles on *C. majus* have been published previously; however none of the reviews described the complete phytochemical and pharmacological profiles of *C. majus* [7, 9, 10]. In this respect, an attempt was made to review its detailed phytochemical and pharmacological potential along with possible drug interaction potential and mechanisms of actions of the major phytochemicals on different aspects of pharmacology. To this, information about the herb was collected by online search using PubMed, Scopus, and Google scholar.

2. Phytochemicals


The therapeutic potentials of *C. majus* are related to its numerous biologically active constituents. Quantitatively the plant contains higher amount of isoquinoline alkaloids (0.27 - 2.25% in aerial parts and 3-4% in root). So far, more than 70 compounds have been isolated

Correspondence:
Pratim Banerji
Ulysses Research Foundation,
125, Rash Behari Avenue, Kolkata
700 029



and identified from this plant including alkaloids, flavonoids, saponins, vitamins (e.g. vitamin A and C), mineral elements, sterols, acids and their derivatives [11]. Extensive phytochemical investigation revealed the presence of variety of alkaloids in different parts of this plant such as benzophenanthridines [chelidonine (1), didehydrochelidonine (2), α -homochelidonine (3), norchelidonine (4), oxychelidonine (5), 10-hydroxychelidonine (6), 10-hydroxyhomochelidonine (7), chelerythrine (8), dihydrochelerythrine (9), norchelerythrine (10), 8-hydroxydihydrochelerythrine (11), 8-acetyldihydrochelerythrine (12), 6-methoxydihydrochelerythrine (13), nitidine (14), dihydronitidine (15), oxynitidine (16), sanguinarine (17), dihydrosanguinarine (18), norsanguinarine (19), oxysanguinarine (20), N-dimethyl-9,10-dihydroxysanguinarine (21), 8-hydroxydihydrosanguinarine (22), 6-acetyl-5,6-dihydrosanguinarine (23), 6-methoxydihydrosanguinarine (24), methyl 2'-(7,8-dihydrosanguinarine-8-yl)acetate (25), chelelutine (26), dihydrochelelutine (27), chelerythrine (28), dihydrochelerythrine (29), chelamine (30), chelidimerine (31), chelamidine (32), angoline (33) and macarpine (34)], isoquinolines [noroxyhydrastinine (35) and turkiyenine (36)], protoberberines [protopine (37) and α -allocryptopine (38)], protoberberines [canadine (39), stylophine (40), corysamine (41), berberine (42), dihydroberberine (43), coptisine (44), dihydrocoptisine (45) and 8-oxycoptisine (46)], aporphines [magnoflorine (47), corydine (48) and norcorydine (49)] and quinolisidine [sparteine (50)] [3, 11]. In addition to these, plant also contains different aromatic and aliphatic acids such as chelidonic acid (51), caffeic acid (52), ferulic acid (53), *p*-coumaric acid (54), citric acid (55), malic acid (56), succinic acid (57), gentisic acid (58), *p*-hydroxybenzoic acid (59) and nicotinic acid (60) [11, 12]. Recently four caffeic acid esters such as 2-(-)-caffeoyl-D-glyceric acid (61), 4-(-)-caffeoyl-L-threonic acid (62), (+)-caffeoyl-L-malic acid (63) and 2-(-)-caffeoyl-L-threonic acid lactone (64) have been identified [13]. Besides, it contains lesser amount of phytosterols [α -spinasterol (65) and ergosterol (66)], polysaccharide [CM-Ala (67)], alcohols [1-hexacosanol (68), chelidoniol, and nonacosanol], flavonoids [rutin (69), quercetin (70) and kaempferol (71)], choline (72), tyramine (73), histamine (74) and saponosides [12, 14-16]. In addition to these organic compounds, 24 essential macro- and microelements including Al, As, B, Ba, Ca, Cd, Co, Cr, Cu, Fe, Hg, K, Li, Mg, Mn, Mo, Na, Ni, P, Pb, S, Ti, V and Zn have been identified in root and herb. Quantitatively, most mineral elements were between 10-65%, especially for potassium (65%) and phosphorus (54%) [17]. Chemical structures of some *C. majus* constituents are presented in Figure 1.




Chelidonine (1)




Didehydrochelidonine (2)

 α -homochelidonine (3)


Norchelidonine (4)




Oxychelidonine (5)




10-hydroxychelidonine (6)




10-hydroxyhomochelidonine (7)




8-acetyldihydrochelerythrine (12)




Chelerythrine (8)




6-methoxydihydrochelerythrine (13)




Dihydrochelerythrine (9)




Nitidine (14)




Norchelerythrine (10)




Dihydranitidine (15)




8-hydroxydihydrochelerythrine (11)




Oxynitidine (16)




Sanguinarine (17)




Dihydrosanguinarine (18)




6-methoxydihydrosanguinarine (24)




Norsanguinarine (19)




Methyl 2'-(7,8-dihydrosanguinarine-8-yl)acetate (25)




Oxysanguinarine (20)




Chelelutine (26)




N-dimethyl-9,10-dihydroxysanguinarine (21)




Dihydrochelelutine (27)




8-hydroxydihydrosanguinarine (22)




Chelerubine (28)




6-acetyl-5,6-dihydrosanguinarine (23)




Dihydrochelerubin (29)




Chelamine (30)




Macarpine (34)




Chelidimerine (31)




Noroxyhydrastinine (35)




Turkiyenine (36)




Protopine (37)




Chelamidine (32)




α -allocryptopine (38)




Angoline (33)




Canadine (39)




Stylopine (40)




Dihydrocoptisine (45)




Corysamine (41)




8-oxycoptisine (46)




Berberine (42)




Magnoflorine (47)




Dihydroberberine (43)




Corydine (48)




Coptisine (44)




Norcorydine (49)




Sparteine (50)




Citric acid (55)




Chelidonic acid (51)




Malic acid (56)




Caffeic acid (52)




Succinic acid (57)




Gentisic acid (58)




Ferulic acid (53)




p-hydroxybenzoic acid (59)




p-coumaric acid (54)




Nicotinic acid (60)




2-(-)-caffeoyl-D-glyceric acid (61)




4-(-)-caffeoyl-L-threonic acid (62)




(+)-caffeoyl-L-malic acid (63)




2-(-)-caffeoyl-L-threonic acid lactone (64)




α -spinasterol (65)




Ergosterol (66)




CM-Ala (67)



1-hexacosanol (68)



Rutin (69)



Quercetin (70)




Fig 1: Chemical structures of *C. majus* constituents.

3. Pharmacological activities

3.1 Antibacterial

C. majus traditionally used as the remedy for toothache. *In vitro* study revealed that the extract of *C. majus* exhibited strong antibacterial activity against *Streptococcus mutans* and the effect of extract was highly related to its chelerythrine content [18]. Kokoska *et al.* reported the antimicrobial activity of the ethanolic root extract of *C. majus* against *Bacillus cereus*, *Candida albicans* and *Salmonella enteritidis* [19]. An immunoactive lectin of *C. majus* was reported to have potent antimicrobial properties against methicillin and vancomycin-resistant Enterococci and Staphylococci [20, 21]. Recent phytochemical analysis of *C. majus* extract led to the isolation of two alkaloidal compounds 8-hydroxydihydroanguinarine and 8-hydroxydihydrochelerythrine which were found to possess strong antibacterial effect against a methicillin-resistant strain of *Staphylococcus aureus* [22]. Miao *et al.* also reported that sanguinarine and chelerythrine and their derivatives showed potent antibacterial activity against *S. aureus*, *E. coli* and *A. hydrophila* [23].

3.2 Antifungal

The aqueous and methanol extracts of *C. majus* (root and shoot) showed significant inhibitory action against various *Fusarium* strains including *F. culmorum*, *F. graminearum*, *F. oxysporum cubense* and *F. solani* [24]. Further, bioassay-guided approach led to the isolation of six alkaloidal compounds 8-hydroxydihydroanguinarine, 8-hydroxydihydrochelerythrine, dihydroanguinarine, dihydrochelerythrine, sanguinarine and

chelerythrine which were reported to show antifungal activity against drug-resistant fungi [25]. The chelerythrine and a mixture of chelerythrine and sanguinarine exerted an antifungal effect against some *Trichophyton* strains, *Microsporum canis*, *Epidermophyton floccosum* and *Aspergillus fumigates* [26]. Recent studies showed that the naturally occurring benzophenanthridine alkaloids (50 mg/ml), sanguinarine and chelerythrine exhibited strong inhibitory action against *Alternaria alternata*, *Curvularia lunata*, *Pyricularia oryza*, *F. solani*, *Valsa mali*, *F. oxysporum* sp. *niveum* and *F. oxysporum* f. sp. *vasinfectum* [27].

3.3 Antiviral

Total alkaloidal extracts of *C. majus* showed antiviral activity against different types of viruses. The ethanol extract of *C. majus* inhibit the growth and development of herpes simplex virus type 1 (HSV-1) [1]. In addition, the crude extract of *C. majus* was found to inhibit HIV-1 and this action was related to its sulphated polyglycosaminoglycan content [28]. *In vitro* study revealed that the benzophenanthridine alkaloidal fractions of different parts showed virucidal activity against HSV-1 and adenovirus type 5 and 12 [29]. The *C. majus* alkaloids such as chelidonic acid ($IC_{50} = 200 \mu\text{g/ml}$) and berberine ($IC_{50} = 100 \mu\text{g/ml}$) were found to have inhibitory action against HIV-1 reverse transcriptase enzyme [30].

3.4 Antiprotozoal

Various alkaloids of *C. majus* reported to inhibit the growth of *Trichomonas vaginalis in vitro*. The alkaloid, sanguinarine also caused the protozoa to undergo deformation followed by disintegration [31].

3.5 Anthelmintic

The ethanol extract of *C. majus* whole plant showed considerable anthelmintic activity against *Dactylogyrus intermedius* with an EC_{50} value 71.5 mg/l. Phytochemical analysis revealed that a benzophenanthridine alkaloid, chelidonic acid was responsible for this activity with an EC_{50} value of 0.48 mg/l [32].

3.6 Antiulcer

C. majus is one of the important constituents of polyherbal formulation, Iberogast[®] used against irritable bowel syndrome. Pharmacological investigation revealed that the extract of *C. majus* dose dependently produced anti-ulcerogenic effect with reduced acid output and the release of leukotrienes and an increased in mucin secretion and prostaglandin E2 (PGE2) release [33]. Recent findings revealed that purified chelidonic acid from *C. majus* reduced inflammation in mice with ulcerative colitis via inhibiting the production of IL-6, tumor necrosis factor- α (TNF- α), cyclooxygenase-2 (COX-2) and hypoxia-inducible factor-1 α (HIF-1 α) [34].

3.7 Hepatoprotective

C. majus is widely used for the treatment of liver diseases. Several researchers have been established the hepatoprotective effect of the crude extract and its alkaloids. *In vivo* study revealed that the administration of crude extract significantly prevented the carbon tetrachloride induced liver damage and p-dimethylaminoazobenzene (p-DAB) induced hepatocarcinogenesis [35, 36]. The crude *C. majus* extract did not alter the normal liver functions; however it prevented the acetaminophen induced elevation of activated thromboplastin, focal hepatocellular necrosis, plasma enzymes (aspartate

aminotransferase and alanine transaminase) and total bilirubin [37]. The phenolic and alkaloidal fractions of *C. majus* showed choleric activity by increasing the bile acid flow in rats and human with liver diseases [38]. In addition the nano-formulation of chelidonine was significantly reduced the cadmium chloride induced oxidative stress and hepatotoxicity in mice [39]. Moreover, various high dilutions (potencies) of *C. majus* extract such as Chelidonium-30 (CH-30) and Chelidonium-200 (CH-200) were also reported to ameliorate the liver dysfunctions by reducing the elevated levels of some toxic markers such as acid and alkaline phosphatases, peroxidases, aspartate aminotransferase, alanine transaminase, glutamate oxaloacetate, glutamate pyruvate transaminases, cholesterol and bilirubin in liver of experimental animals [40, 41].

3.8 Hypolipidemic

Recent *in vivo* study showed the hypolipidemic potential of ethanolic *C. majus* extract in rats. Oral administration of the extract (100-300 mg/kg) dose dependently suppressed the serum concentration of triglyceride, low density lipoprotein and high density lipoprotein in hypercholesterolemic rats [42].

3.9 Radioprotective

There was no evidence for the radiation protective effect of *C. majus* extract; however a polysaccharide, CM-Ala, isolated from this plant which considerably reduced the time required for the reconstitution of hematopoietic cells after irradiation treatment [43]. Other studies demonstrated that the ukrain, a semi-synthetic thiophosphoric acid derivative of alkaloid chelidonine, increased survival and enhanced the restoration of hemopoiesis process of irradiated experimental animals [44].

3.10 Antioxidant

In vitro studies demonstrated that the extracts of *C. majus* showed potential antioxidant activity [12]. Phytochemical analysis revealed that the anti-oxidant capacity of *C. majus* extract was greatly depends on its total alkaloid content [45]. *In vitro* study revealed that the oral administration of the polyphenol extracts from different parts of *C. majus* (flowers, leaves, roots, seeds and stems) were found to scavenge various free radicals such as hydroxyl (HO \cdot) and peroxy (RCOO \cdot) radicals, hypochlorite (ClO \cdot) and superoxide (O $_2\cdot^-$) anions, singlet oxygen (1O_2) and hydrogen peroxide (H $_2O_2$) [5]. The antioxidative effect of *C. majus* extract was mediated through the activation of transcription factor, FOXO3a followed by the upregulation of major antioxidant enzymes such as catalase and manganese superoxide dismutase (MnSOD) [46].

3.11 Anti-inflammatory and analgesic

Traditionally, *C. majus* is used for the treatment of numerous inflammatory diseases. *In vivo* study demonstrated that the extract of *C. majus* considerably reduced the itching behavior, ear thickness, and the levels of serum IgE, TNF- α and IL-4 in atopic dermatitis mice [47]. Several active compounds have been isolated from this herb such as stylophine, chelidonine, 8-hydroxydihydrosanguinarine, chelerythrine, sanguinarine which showed strong inhibitory actions on LPS-induced production of nitric oxide (NO), PGE $_2$, TNF- α , IL-1 β , IL-6 and induction of COX-2 and the expression inducible nitric oxide synthase (iNOS) mRNA in macrophages [48-50]. *In vivo* study showed that sanguinarine, chelerythrine and quaternary benzophenanthridine fraction of *C. majus* significantly reduced carrageenan-induced rat paw oedema and sanguinarine showed higher anti-inflammatory potential than chelerythrine [48].

Recently, the tail-flick studies in mice and rats revealed that the *C. majus* extract (200 mg/kg) and chelidonine (5 mg/kg) showed strong analgesic activity than aspirine [51, 52]. Molecular study revealed that the extract suppressed gamma-aminobutyric acid (GABA) activated ion currents and elevated glutamate-activated ion currents in rat periaqueductal gray (PAG) neurons. These mechanisms were suggested to play important role in the analgesic actions of *C. majus* extract [53, 54].

3.12 Anti-arthritis

The extract of *C. majus* showed potent anti-arthritis activity in collagen-induced arthritis model of mice [55]. Administration of *C. majus* extract (40 and 400 mg/kg) significantly suppressed collagen-induced arthritis which was characterized by decreased production of TNF- α , IL-6, IFN- γ , B cells, $\gamma\delta$ T cells, levels of IgG and IgM rheumatoid arthritis factor, and increased proportion of regulatory T cells [55].

3.13 Antialzheimer

Acetylcholine is a key factor in the transmission of nerve impulses from one neuron to other in the neuromuscular junction. It is the key hydrolyzing substrate for the enzyme acetylcholinesterase in Alzheimer's disease. The ethanol extract of the aerial parts showed strong acetylcholinesterase (AChE) inhibitory action [3]. Several active alkaloids such as 6-ethoxydihydrochelerythrine, 6-ethoxydihydrosanguinarine, 8-hydroxydihydrochelerythrine, 8-hydroxydihydrosanguinarine, sanguinarine, chelidonine, chelerythrine and berberine have been isolated from the roots and aerial parts of greater celandine. Recent *in vitro* studies showed that 8-hydroxydihydrochelerythrine, 8-hydroxydihydrosanguinarine, sanguinarine, chelerythrine and berberine strongly inhibited the activity of AChE, whereas chelidonine, 6-ethoxydihydrochelerythrine and 6-ethoxydihydrosanguinarine inhibited AChE and butyrylcholinesterase (BuChE) activity [3, 56, 57].

3.14 Immunomodulatory

In the previous section it has been described that the production of inflammatory mediators was inhibited by various constituents of greater celandine. However, the *C. majus* extract reported to improve tonsillar function, cellular and humoral immunity and nonspecific resistance [58]. The extract in combination with recombinant interferon- γ , increased the production of NO and TNF- α in mouse peritoneal macrophages [59]. Recently, a *C. majus* alkaloid, 6-acetonyl-5,6-dihydrosanguinarine, was also found to increase the production of inflammatory cytokines TNF- α , IL-6, and IL-8 in macrophages and dendritic cells [60]. A protein-bound polysaccharide, CM-Ala, has been isolated from the water extract of *C. majus* which was found to increase the production of NO in peritoneal macrophages. CM-Ala was also induced the proliferation of splenocytes and increased the population of granulocyte macrophage-colony forming cells (GM-CFC) [14].

3.15 Natriuretic and antidiuretic

The cadmium is a potent nephrotoxicant and it accumulates and persists in the kidneys. Oral administration of methanol extract of *C. majus* leaves led to restore kidney weight, serum electrolytes, urea and creatinine, urinary excretion of electrolytes and urine volume towards normal values in cadmium-intoxicated rats [61].

3.16 Anticancer

It was determined that the *C. majus* extract suppressed the genotoxic effect of nalidixic acid and furacilin in two different bacterial test systems [62]. The extract of *C. majus* was reported to possess anticancer potentials against variety of chemical carcinogens and inhibited carcinogen-induced angiogenesis and fibroblast proliferation [63]. Several reports demonstrated the anticancer potential of various *C. majus* alkaloids such as chelidonine, sanguinarine, berberine, chelerythrine and coptisine [64, 65]. Chelidonine and sanguinarine induced apoptosis in human lymphoblastic leukaemia cells via caspase 9 and 3 activation and an increase of pro-apoptotic Bax protein [65]. Recently, it was demonstrated that the chelidonine and alkaloidal rich extract (protoberberine and benzophenanthridine) of *C. majus* overcame the multidrug resistance of different cancer cells by apoptosis and cytotoxic effects of chemotherapeutics [66]. Colombo *et al.* reported that the methanol extract of *C. majus* and the coptisine alkaloid showed strong cytotoxicity against human colon carcinoma [67]. However, other constituents including a protein-bound polysaccharide, CM-Ala and lectin isolated from *C. majus* were also suppressed the growth of cancer cells, *in vitro* [14, 21]. The ukrain, a semi-synthetic preparation of chelidonine

alkaloid, was demonstrated as a potential anticancer agent against the cancer of lung, pancreas, prostate, breast and urinary bladder [68-72]. Besides, the homeopathic preparations of *C. majus* extract such as CH30 and CH200 showed anti-tumor activity and favorably modulated various toxicity marker enzymes such as acid and alkaline phosphatases, peroxidases, glutamate oxaloacetate and glutamate pyruvate transaminases in liver, kidney and spleen of carcinogen-treated mice [40].

3.17 Antispasmodic

The hydro-alcoholic extract of *C. majus* and its active constituents were found to induce relaxation of acetylcholine and barium-chloride induced contraction of guinea-pig ileums [73, 74]. The alkaloids, chelidonine and protopine at concentrations of 1×10^{-5} g/ml organ bath were markedly induced the relaxation (68.8% and 54.8%, respectively) of barium-chloride induced guinea-pig ileums contraction [74]. Another study also revealed the significant contribution of coptisine and (+)-caffeoylmalic acid to the total antispasmodic activity of *C. majus* extract [73]. Besides these pharmacological activities, molecular mechanisms of the major active compounds of *C. majus* on different aspects of the pharmacological actions are summarized in Table 1.

Table 1: Mechanism of actions of major phytochemicals of *C. majus* on different aspects of pharmacology.

Constituents	Biological activity	Mechanism of actions
Chelidonine	Anticancer	Induced apoptosis by up-regulating the expression of apoptotic genes such as p53, Bax, caspase 3 and caspase 8 and the down-regulation of the expression of antiapoptotic genes such as Bcl-2, cyclin D1, protein kinase B, Janus kinase 3, E6 and E7 oncoproteins [66, 75].
	Hepatoprotective	Reduced ROS generation, lipid peroxidation and attenuated inflammatory cascade in the liver [39].
	Anti-alzheimer	Inhibited the activity of AChE and BChE [57].
Chelerythrine	Anti-inflammatory	Decreased the synthesis of monocyte chemo-attractant protein 1 (MCP-1), IL-6, TNF- α , PGE2 and NO [76, 77].
	Anti-alzheimer	Inhibited AChE and BChE activity and β -amyloid aggregation [78].
	Anticariogenic	Inhibited cell surface hydrophobicity and adherence by the inhibition of glucosyltransferase and extra-cellular synthesis of water-insoluble glucans [79].
	Nephroprotective	Scavenged free radicals through the inhibition of a PKC pathway and inhibited the production of PGE2 [80].
	Antimycobacterial	Triggered transcriptional changes in the Mycobacterial genome [81].
	Gastroprotective	Inhibited the secretion of inflammatory mediators in gastric mucosa by regulating NF- κ B signalling pathway [82].
	Antiplatelet	Inhibited thromboxane formation and phosphoinositides breakdown [83].
	Anticancer	Induced apoptosis via dissipation of mitochondrial membrane potential and activation of caspase 9 and 3 [84].
Dihydrochelerythrine	Antifungal	Inhibited the growth of mycelium and the germination of spores [85].
	Anticancer	Induced apoptosis via dissipation of mitochondrial membrane potential and activation of caspase 9 and 3 [84].
8-hydroxydihydrochelerythrine	Anti-alzheimer	Inhibited the activity of AChE and BChE [3].
6-acetyl-5,6-dihydrosanguinarine	Immunostimulatory	Increased the production of TNF- α , IL-6, IL-8 and activated NF- κ B [60].
Sanguinarine	Antibacterial	Altered membrane permeability and inhibited bacterial DNA synthesis as well as cytokinesis [86, 87].
	Anticancer	Induced apoptosis via activation of caspase 3, 7, 8, and 9, dissipation of mitochondrial membrane potential, increase pro-apoptotic and decrease anti-apoptotic proteins formation [88-90].
	Anti-inflammatory	Decreased the expression of MCP-1, IL-6, TNF- α , and NF- κ B genes and increased the expression of IL-1 receptor antagonist [76, 91].
	Antiplatelet	Activated adenylate cyclase, inhibited Ca ²⁺ mobilization, thromboxane B2 production and COX-1 activity [92].
	Immunomodulatory	Inhibited the degranulation and phagocytosis of polymorphonuclear cells (PMN) [93].
Dihydrosanguinarine	Anti-alzheimer	Inhibited the activity of AChE [56].
	Anticancer	Induced apoptosis via activation of caspase 3 and 9, dissipation of mitochondrial membrane potential and the damage of plasma membrane asymmetry [90].
Dihydrosanguinarine	Anticancer	Induced apoptosis via activation of caspase 3 and 9, dissipation of mitochondrial membrane potential and the damage of plasma membrane asymmetry [90].
	Antifungal	Inhibited the growth of mycelium and the germination of spores [85].

Constituents	Biological activity	Mechanism of actions
8-hydroxydihydroanguinarine	Anti-alzheimer	Inhibited the activity of AChE and BChE [3].
Berberine	Antimicrobial	Inhibited DNA and protein biosynthesis in bacteria, fungi and viruses [86].
	Antinephritic	Improved renal hemodynamics by changing prostanoid synthesis [94].
	Anticancer	Inhibited the activity of DNA topoisomerase I, activator protein 1 and COX-2 and inhibited the expression of viral oncoproteins E6 and E7 [95-97].
	Antiangiogenic	Inhibited the expressions proangiogenic factors such as HIF-1 α , vascular endothelial growth factor (VEGF), COX-2 and iNOS [98].
	Cardioprotective	Regulated AMP-activated protein kinase activity in heart [99].
	Hypoglycemic	Activated the transport activity of glucose transporter 1 (GLUT1) [100].
	Hepatoprotective	Reduced oxidative stress by scavenging free radicals and inhibited the production of inflammatory mediators in the liver [101].
	Anti-inflammatory	Inhibited the expressions of NO, NF- κ B and proinflammatory cytokines such as IL-1 β , IL-6, TNF- α , and granulocyte macrophage colony-stimulating factor (GM-CSF) [98].
	Antiviral	Interfered in the viral DNA synthesis [102].
	Anxiolytic	Increased the production of monoamines in the brain and decreased the activity of serotonergic system via activation of somatodendritic 5-HT1A autoreceptors and the inhibition of postsynaptic 5-HT1A and 5-HT2 receptors [103].
Anti-alzheimer	Inhibited the activity of AChE [56].	
Protopine	Antioxidant	Enhanced the activity of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase and catalase [104].
	Hepatoprotective	Inhibited microsomal lipid peroxidation [105].
	Anti-thrombotic	Inhibited platelet aggregation by inhibiting thromboxane formation, phosphoinositides breakdown and decreased intracellular concentration of Ca ²⁺ [106].
	Analgesic	Inhibited the release of Ca ²⁺ (calcium system) and regulated the opioid and adrenergic systems [107].
	Anti-inflammatory	Inhibited the production of NO, COX-2, PGE2, IL-1 β , IL-6, and TNF- α through blocking the activation of NF- κ B and phosphorylation of mitogen-activated protein kinase [108].
	Anticancer	Induced apoptosis by increasing cyclin-dependent kinase 1 activity and down-regulating the anti-apoptotic Mcl-1 and Bcl-2 phosphorylation [109].
	Relaxant	Inhibited the intracellular release of Ca ²⁺ [110].
Anti-alzheimer	Inhibited the activity of AChE [111].	
Allocryptopine	Relaxant	Induced relaxation of smooth muscle by inhibiting the activity of phosphodiesterase and elevating the cellular level of cAMP [112].
	Antiarrhythmic	Inhibited the transient outward potassium current [113].
Coptisine	Vasorelaxant	Activated K ⁺ channels and inhibited the extracellular influx of Ca ²⁺ [114].
	Anti-inflammatory	Attenuated the production of proinflammatory cytokines such as IL-1 β , IL-6, and TNF- α [115].
	Cardioprotective	Inhibited myocardial cells apoptosis via upregulation of Bcl-2 protein, inhibition of caspase-3 activation and Rho/Rho-kinase signalling pathway [115].
	Antinephritic	Improved renal hemodynamics by changing prostanoid synthesis [94].
Chelidonic acid	Anti-inflammatory	Inhibited the production of IL-6, TNF- α , COX-2, PGE2, and HIF-1 α and suppressed the activation and expression of caspase 1 [34,116].
	Anti-allergic	Inhibited eosinophils and mast cells infiltration and decreased the activity of caspase 1 and the expressions of IL-1 β and COX-2 in nasal mucosa [117].
Stylopine	Anti-inflammatory	Inhibited NO, PGE2, TNF- α , IL-1 β , and IL-6 production and COX-2 activity [49].
Nitidine	Anti-malarial	Inhibited the formation of β -haematin [118].
	Anticancer	Inhibited the STAT3 signaling pathway and induced cell apoptosis by up-regulating pro-apoptotic proteins (e.g. Bax, cleaved caspase-9 and -3 and cleaved PARP) and down-regulating anti-apoptotic proteins (e.g. Bcl-2 and PARP) [119,120].
	Anti-inflammatory	Inhibited the production of TNF- α , IL-1 β and IL-6 via suppressing the phosphorylation of mitogen-activated protein kinases and the activity of NF- κ B [121].
	Anticancer	Inhibited STAT3 signaling pathway via preventing STAT3 phosphorylation and its target gene expression [119].
Dihydrontidine	Anticancer	Induced apoptosis via regulating the expression of cyclin-dependent kinase 2 and cyclin E family genes and up-regulating the cell death related genes [122].
Sparteine	Antiarrhythmic	Inhibited Na ⁺ and K ⁺ channels [123].
Angoline	Anticancer	Inhibited STAT3 phosphorylation and its target gene expression [124].

4. Toxicity

C. majus has wide range of clinical applications; however some investigators reported its adverse effects in animals and human. It has been reported that the ingestion *C. majus* latex causes severe irritation of the oral mucosa, throat, stomach, and gut. When the plant is directly applied on skin, it causes irritation, blisters, and allergic contact dermatitis [125]. Recently, there is a controversy between hepatoprotective and

hepatotoxic effects of *C. majus*. Several investigators demonstrated the development of liver toxicity after consumption of *C. majus* extract or herbal preparations containing *C. majus* extract [125-127]. *In vitro* study revealed that the alkaloids of *C. majus* such as chelerythrine, sanguinarine, berberine, coptisine, protopine and allocryptopine inhibited liver respiration in mice via inhibition of mitochondrial enzymes such as NADH dehydrogenase and succinate

dehydrogenase [128].

5. Herb-drug interactions

Many people concomitantly use herbal drugs with prescription and non-prescription medications. Herbal drugs and their active compounds were reported to interact with other medications which led to develop serious side effects and/or reduced the efficacy of the medications [129]. Currently there is no information reported on the drug interaction potential of the extract of *C. majus*. However, there were few reports demonstrated the possible drug interaction of the purified active compounds of *C. majus*. Effects of some active constituents of *C. majus* on various drug metabolizing cytochrome P450 (CYP) enzymes are given in Table 2.

Table 2: Inhibition of drug metabolizing CYP enzymes by the alkaloids of *C. majus*.

Active compounds	Drug interactions potential
Sanguinarine	Inhibited the activity of CYP1A1, CYP1A2, CYP3A1, CYP3A4, CYP2C8, CYP2C9, CYP2D1, and CYP2E1 enzymes [130, 131].
Chelerythrine	Inhibited the activity of CYP1A1 enzyme [132].
Chelidonine	Inhibited the activity of CYP3A4 enzyme [66].
Berberine	Inhibited the activity of CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP2C9, CYP3A4 CYP3A11 and CYP2D22 enzymes [133-135].
Protopine	Inhibited the activity of CYP1A1, CYP1A2, CYP2C19, CYP2B6, CYP2D6 and CYP3A4 enzymes [136].
Allocryptopine	Inhibited the activity of CYP1A2, CYP2B6, CYP2C8, CYP2D6 and CYP3A4 enzymes [136].
Canadine	Inhibited the activity of CYP1A2, CYP2B6, CYP2C19, CYP2D6 and CYP3A4 enzymes [136].
Corydine	Inhibited the activity of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 enzymes [136].
Stylopine	Inhibited the activity of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 enzymes [136].

6. Current drugs and future prospect

Since ancient time, the medicinal plants have been considered as the alternative treatments of various diseases and ailments. However, further attention should be required to discover molecular mechanisms behind the therapeutic potential of herbal extracts and their isolated active compounds to promote their commercial uses. Past few decades of pharmacological investigations on *C. majus* extract and its purified bioactive compounds have been shown to possess immense therapeutic potential as antimicrobial, hepatoprotective, anticancer, antioxidant, antialzheimer, immunomodulatory, anti-inflammatory and analgesic agent *in vivo* and *in vitro* studies. Therefore, the pharmacological activities of *C. majus* as well as its purified compounds open up interesting avenues for further research and offer new perspectives in the treatment of these diseases. Different parts of *C. majus* have been used in various polyherbal medicines as well as in combined homeopathic medicines. However, in homeopathic medicine, high-dilutions (potencies) of *C. majus* extract have been also used to treat numerous diseases. Some *C. majus* containing herbal and homeopathic products are already available in the market, including Gastol™ (Ulysses Pharmaceuticals, Kolkata, India) for hyperacidity; Hepeel® (Heel Healthcare, Baden-Baden, Germany) for liver disorders; and Iberogast®

(Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany) for gastrointestinal disorders [137-138]. Recently, a semisynthetic derivative of *C. majus* alkaloid (chelidonine) known as Ukrain™ (Nowicky Pharma, Vienna, Austria) are commercially available to treat cancer.

The extract of *C. majus* as well as its different purified compounds exhibited a wide range of pharmacological activities such as anti-inflammatory, antimicrobial, anticancer, antioxidant, hepatoprotective, natriuretic and antidiuretic that validate some of the traditional uses of *C. majus*. Immunomodulatory, hypolipidemic and radioprotective potentials of the extract of *C. majus* and its constituents needs to be further evaluated to establish their molecular mechanisms behind such therapeutic properties. The antialzheimer effect of crud extract and its various pure compounds encourage future research for the development of new drug for Alzheimer's disease. Along with various *in vitro* and animal studies, no adequate clinical studies have not been conducted to evaluate its various medicinal effects. Therefore, to justify acclaimed efficacies of *C. majus* and purified compounds against various diseases, well-designed clinical studies are warranted. The hepatoprotective versus hepatotoxic effect of *C. majus* is still a controversial issue; so further toxicological investigations on *C. majus* are further warranted to resolve this issue. Few reports demonstrated the negative interaction between drug metabolizing enzymes and the purified compounds of *C. majus*. However, more details studies are required to evaluate possible herb-drug and herb-herb interaction of *C. majus* including its various purified active compounds. Further studies on the Pharmacokinetics, bioavailability and metabolism of *C. majus* bioactive components in animals as well as in humans are another aspect of future research.

7. Conclusion

C. majus offers a wide range of ethnobotanical and modern utilizations. *In vitro* and *in vivo* studies exhibit numerous therapeutic potential of *C. majus* and its major active compounds with minimal side effects. Though its effect on liver becomes a controversial issue, further studies are required to resolve of this issue. Considering the therapeutic potential of *C. majus* and its use in herbal medicines, it is essential to conduct clinical studies for assessing efficacy and safety of this herb for human uses.

8. Conflicts of Interest

There are no known conflicts of interest associated with this publication.

9. References

1. Monavari SH, Shahrabadi MS, Keyvani H, Bokharaei-Salim F. Evaluation of *in vitro* antiviral activity of *helidonium majus* L. against herpes simplex virus type-1. African Journal of Microbiology Research 2012; 6(20):4360-4364.
2. Ciric A, Vinterhalter B, Savikin-Fodulovic K, Sokovic M, Vinterhalter D. Chemical analysis and antimicrobial activity of methanol extracts of celandine (*Chelidonium majus* L.) plants growing in nature and cultured *in vitro*. Archives of Biological Sciences 2008; 60(1):7-8.
3. Cho KM, Yoo ID, Kim WG. 8-hydroxydihydrochelerythrine and 8-hydroxydihydrosanguinarine with a potent acetylcholinesterase inhibitory activity from *Chelidonium*

- majus* L. Biological and Pharmaceutical Bulletin 2006; 29(11):2317-2320.
4. Aljuraissy YH, Mahdi NK, Al-Darraj MNJ. Cytotoxic effect of *Chelidonium majus* on cancer cell. Al-Anbar Journal of Veterinary Sciences 2012; 5(1):85-90.
 5. Papuc C, Crivineanu M, Nicorescu V, Predescu C, Rusu E. Scavenging activity of reactive oxygen species by polyphenols extracted from different vegetal parts of celandine (*Chelidonium majus*). Chemiluminescence Screening. Revista de Chimie 2012; 63(2):193-197.
 6. Pieroni A, Dibra B, Grishaj G, Grishaj I, Gjon Maçai S. Traditional phytotherapy of the Albanians of Lepushe, Northern Albanian Alps. Fitoterapia 2005; 76(3-4):379-399.
 7. Gilca M, Gaman L, Panait E, Stoian I, Atanasiu V. *Chelidonium majus* - an integrative review: Traditional knowledge versus modern findings. Forsch Komplementmed 2010; 17(5):241-248.
 8. Biswas SJ, Khuda-Bukhsh AR. Effect of a homeopathic drug, *Chelidonium*, in amelioration of p-DAB induced hepatocarcinogenesis in mice. BMC Complementary and Alternative Medicine 2002; 2:1-12.
 9. Taborska E, Bochorakova H, Dostal J, Paulova H. The greater celandine (*Chelidonium majus* L.) - review of present knowledge. Ceska a Slovenska Farmacie 1995; 144(2):71-75.
 10. Colombo ML, Bosisio E. Pharmacological activities of *Chelidonium majus* L. (Papaveraceae). Pharmacology Research 1996; 33(2):127-134.
 11. Kopyt'ko YF, Dargaeva TD, Sokol'skaya TA, Grodnitskaya EI, Kopnin AA. New methods for the quality control of a homeopathic matrix tincture of Greater Celandine. Pharmaceutical Chemistry Journal 2005; 39(11):603-609.
 12. Hadaruga DI, Hadaruga NG. Antioxidant activity of *Chelidonium majus* L. extracts from the Banat county. Journal of Agroalimentary Processes and Technologies 2009; 15(3):396-402.
 13. Hahn R, Nahrstedt A. Hydroxycinnamic acid derivatives, caffeoylmalic and new caffeoylaldonic acid esters, from *Chelidonium majus*. Planta Medica 1993; 59(1):71-75.
 14. Song JY, Yang HO, Pyo SN, Jung IS, Yi SY, Yun YS. Immunomodulatory activity of protein-bound polysaccharide extracted from *Chelidonium majus*. Archives of Pharmacal Research 2002; 25(2):158-164.
 15. WHO. Monographs on medicinal plants commonly used in the Newly Independent States (NIS). Geneva: WHO Press, 2010.
 16. Parvu M, Vlase L, Fodorpataki L, Parvu O, Rosca-Casian O, Bartha C *et al.* Chemical composition of celandine (*Chelidonium majus* L.) extract and its effects on *Botrytis tulipae* (Lib.) Lind fungus and the tulip. Notulae Botanicae Horti Agrobotanici Cluj-Napoca 2013; 41(2):414-426.
 17. Sarkozi A, Then Szentmihalyi MK. Mineral element content of greater celandine (*Chelidonium majus* L.). Acta Alimentaria 2005; 34(2):113-120.
 18. Cheng RB, Chen X, Liu SJ, Zhang XF, Zhang GH. Experimental study of the inhibitory effects of *Chelidonium majus* L. extractive on *Streptococcus mutans* *in vitro*. Shanghai Journal of Stomatology 2006; 15(3):318-320.
 19. Kokoska L, Polesny Z, Rada V, Nepovim A, Vanek T. Screening of some Siberian medicinal plants for antimicrobial activity. Journal of Ethnopharmacology 2002; 82(1):51-53.
 20. Fik E, Gozdzicka-Jozefiak A, Haertle T, Mirska I, Kedzia W. New plant glycoprotein against methicillin resistant Staphylococci and Enterococci. Acta microbiologica Polonica 1997; 46(3):325-327.
 21. Fik E, Wolun-Cholewa M, Kistowska M, Warchol JB, Gozdzicka-Jozefiak A. Effect of lectin from *Chelidonium majus* L. on normal and cancer cells in culture. Folia Histochemica et Cytobiologica 2001; 39(2):215-216.
 22. Zuo GY, Meng FY, Hao XY, Zhang YL, Wang GC, Xu GL. Antibacterial alkaloids from *Chelidonium majus* Linn (Papaveraceae) against clinical isolates of methicillin-resistant *Staphylococcus aureus*. Journal of Pharmacy and Pharmaceutical Sciences 2008; 11(4):90-94.
 23. Miao F, Yang XJ, Zhou L, Hu HJ, Zheng F, Ding XD *et al.* Structural modification of sanguinarine and chelerythrine and their antibacterial activity. Natural Product Research 2011; 25(9):863-875.
 24. Matos OC, Baeta J, Silva MJ, Pinto Ricardo C. Sensitivity of *Fusarium* strains to *Chelidonium majus* L. extracts. Journal of Ethnopharmacology 1999; 66(2):151-158.
 25. Meng F, Zuo G, Hao X, Wang G, Xiao H, Zhang J *et al.* Antifungal activity of the benzo[c]phenanthridine alkaloids from *Chelidonium majus* Linn against resistant clinical yeast isolates. Journal of Ethnopharmacology 2009; 125(3):494-496.
 26. Hejtmankova, N, Walterova D, Preininger V, Simanek V. Antifungal activity of quaternary benzo [c] phenanthridine alkaloids from *Chelidonium majus*. Fitoterapia 1984; 55:291-294.
 27. Hou Z, Yang R, Zhang C, Zhu LF, Miao F, Yang XJ *et al.* 2-(Substituted phenyl)-3,4-dihydroisoquinolin-2-iums as novel antifungal lead compounds: Biological evaluation and structure-activity relationships. Molecules 2013; 18(9):10413-10424.
 28. Gerencer M, Turecek PL, Kistner O, Mitterer A, Savidis-Dacho H, Barrett NP. *In vitro* and *in vivo* anti-retroviral activity of the substance purified from the aqueous extract of *Chelidonium majus* L. Antiviral Research 2006; 72(2):153-156.
 29. Kery RY, Horvath J, Nasz I, Verzar-Petri G, Kulcsar G, Dan P. Antiviral alkaloid in *Chelidonium majus* L. Acta pharmaceutica Hungarica 1987; 57(1-2):19-25.
 30. Tan GT, Pezzuto JM, Kinghorn AD, Hughes SH. Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. Journal of Natural Product 1991; 54(1):143-154.
 31. Bodalski T, Pelezarskaund H, Ujec M. Action of some alkaloids of *Chelidonium majus* on *Trichomonas vaginalis* *in vitro*. Archivum Immunologiae et Therapiae Experimentalis 1958; 6:705-711.
 32. Yao JY, Zhou ZM, Pan XY, Hao GJ, Li XL, Xu Y *et al.* *In vivo* anthelmintic activity of chelidonine from *Chelidonium majus* L. against *Dactylogyrus intermedius* in *Carassius auratus*. Parasitology Research 2011; 109(5):1465-1469.
 33. Khayyal MT, el-Ghazaly MA, Kenawy SA, Seif-el-Nasr M, Mahran LG, Kafafi YA *et al.* Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittelforschung 2001; 51(7):545-553.
 34. Kim DS, Kim SJ, Kim MC, Jeon YD, Um JY, Hong SH. The therapeutic effect of chelidonic acid on ulcerative

- colitis. *Biological & Pharmaceutical Bulletin* 2012; 35(5):666-671.
35. Mitra S, Sur RK, Roy A, Mukherjee AS. Effect of *Chelidonium majus* L. on experimental hepatic tissue injury. *Phytotherapy Research* 1996; 10(4):354-356.
 36. Biswas SJ, Bhattacharjee N, Khuda-Bukhsh AR. Efficacy of a plant extract (*Chelidonium majus* L.) in combating induced hepatocarcinogenesis in mice. *Food and Chemical Toxicology* 2008; 46(5):1474-1487.
 37. Mazzanti G, Di Sotto A, Di Giacomo S, Durazzi F, Mariani P, Nicoletti M *et al.* *Chelidonium majus* L. does not potentiate the hepatic effect of acetaminophen. *Experimental and Toxicologic Pathology* 2013; 65(7-8):1117-1120.
 38. Vahlensieck U, Hahn R, Winterhoff H, Gumbinger HG, Nahrstedt A, Kemper FH. The effect of *Chelidonium majus* herb extract on choleresis in the isolated perfused rat liver. *Planta Medica* 1995; 61(3):267-271.
 39. Paul A, Das J, Das S, Samadder A, Khuda-Bukhsh AR. Poly (lactide-co-glycolide) nano-encapsulation of chelidonine, an active bioingredient of greater celandine (*Chelidonium majus*), enhances its ameliorative potential against cadmium induced oxidative stress and hepatic injury in mice. *Environmental Toxicology and Pharmacology* 2013; 36(3):937-947.
 40. Biswas SJ, Khuda-Bukhsh AR. Evaluation of protective potentials of a potentized homeopathic drug, *Chelidonium majus*, during azo dye induced hepatocarcinogenesis in mice. *Indian Journal of Experimental Biology* 2004; 42(7):698-714.
 41. Banerjee A, Pathak S, Biswas SJ, Roy-Karmakar S, Boujedaini N, Belon P *et al.* *Chelidonium majus* 30C and 200C in induced hepato-toxicity in rats. *Homeopathy* 2010; 99(3):167-176.
 42. Zarei A, Changizi-Ashtiyani S, Rezaei A, Sheidaee H, Nabiyoni F. The effect of *Chelidonium majus* extract on the lipid profile and activity of pituitary-gonadal axis in hypercholesterolemic rats. *Zahedan Journal of Research in Medical Sciences* 2014; 16(10):18-22.
 43. Song JY, Yang HO, Shim JY, Ji-Yeon-Ahn, Han YS, Jung IS *et al.* Radiation protective effect of an extract from *Chelidonium majus*. *International Journal of Hematology* 2003; 78(3):226-232.
 44. Boyko VN, Belskiy SN. The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect. *Drugs under Experimental and Clinical Research* 1998; 24(5-6):335-337.
 45. Then M, Szentmihalyi K, Sarkozi A, Varga IS. Examination on antioxidant activity in the greater celandine (*Chelidonium majus* L.) extracts by FRAP method. *Acta Biologica Szegediensis* 2003; 47(1-4):115-117.
 46. Heo JI, Kim JH, Lee JM, Lim SS, Kim SC, Park JB *et al.* Antioxidant activity and its mechanism of *Chelidonium majus* extract. *Korean Journal of Medicinal Crop Science* 2013; 21(2):136-141.
 47. Yang G, Lee K, Lee MH, Kim SH, Ham IH, Choi HY. Inhibitory effects of *Chelidonium majus* extract on atopic dermatitis-like skin lesions in NC/Nga mice. *Journal of Ethnopharmacology* 2011; 138(2):398-403.
 48. Lenfeld J, Kroutil M, Marsalek E, Slavik J, Preininger V, Simanek V. Anti-inflammatory activity of quaternary benzophenanthridine alkaloids from *Chelidonium majus*. *Planta Medica* 1981; 43(2):161-165.
 49. Jang SI, Kim BH, Lee WY, An SJ, Choi HG, Jeon BH *et al.* Stylopine from *Chelidonium majus* inhibits LPS-induced inflammatory mediators in RAW 264.7 cells. *Archives of Pharmacal Research* 2004; 27(9):923-929.
 50. Park JE, Cuong TD, Hung TM, Lee I, Na M, Kim JC *et al.* Alkaloids from *Chelidonium majus* and their inhibitory effects on LPS-induced NO production in RAW264.7 cells. *Bioorganic & Medicinal Chemistry Letters* 2011; 21(23):6960-6963.
 51. Yilmaz BS, Ozbek H, Citoglu GS, Ugraş S, Bayram I, Erdogan E. Analgesic and hepatoprotective effects of *Chelidonium majus* L. *Journal of Faculty of Pharmacy of Ankara* 2007; 36(1):9-20.
 52. Citoglu GS, Ozbek H, Acikara OB, Gacs EB. Isolation of chelidonine as an analgesic compound from *Chelidonium majus* L. *Journal of Faculty of Pharmacy of Ankara* 2009; 38(1):9-16.
 53. Kim Y, Shin M, Chung J, Kim E, Koo G, Lee C *et al.* Modulation of *Chelidonium* herba on GABA activated chloride current in rat PAG neurons. *The American Journal of Chinese Medicine* 2001; 29(2):265-279.
 54. Shin MC, Jang MH, Chang HK, Lim S, Han SM, Park HJ, *et al.* Modulation of *Chelidonium* herba on glycine-activated and glutamate-activated ion currents in rat periaqueductal gray neurons. *Clinica Chimica Acta* 2003; 337(1-2):93-101.
 55. Lee YC, Kim SH, Roh SS, Choi HY, Seo YB. Suppressive effects of *Chelidonium majus* methanol extract in knee joint, regional lymph nodes, and spleen on collagen-induced arthritis in mice. *Journal of Ethnopharmacology* 2007; 112(1):40-48.
 56. Kuznetsova LP, Nikol'skaia EB, Sochilina EE, Faddeeva MD. The inhibition enzymatic hydrolysis of acetylthiocholine by acetylcholinesterase using principal alkaloids isolated from celandine and macleya and their derivatives. *Tsitologiya* 2001; 43(11):1046-1050.
 57. Cahlikova L, Opletal L, Kurfurst M, Macakova K, Kulhankova A, Hostalkova A. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from *Chelidonium majus* (Papaveraceae). *Natural Product Communication* 2010; 5(11):1751-1754.
 58. Khmel'nitskaia NM, Vorob'ev KV, Kliachko LL, Ankhimova ES, Kosenko VA, Tyrnova EV *et al.* A comparative study of conservative treatment schemes in chronic tonsillitis in children. *Vestnik Otorinolaringologii* 1998; (4):39-42.
 59. Chung HS, An HJ, Jeong HJ, Won JH, Hong SH, Kim HM. Water extract isolated from *Chelidonium majus* enhances nitric oxide and tumour necrosis factor-alpha production via nuclear factor-kappaB activation in mouse peritoneal macrophages. *The Journal of Pharmacy and Pharmacology* 2004; 56(1):129-134.
 60. Kim DH, Lee JH, Park S, Oh SS, Kim S, Kim DW *et al.* 6-Acetyl-5,6-dihydroanguinarine (ADS) from *Chelidonium majus* L. triggers proinflammatory cytokine production via ROS-JNK/ERK-NFkappaB signaling pathway. *Food and Chemical Toxicology* 2013; 58:273-279.
 61. Koriem KM, Arbid MS, Asaad GF. *Chelidonium majus* leaves methanol extract and its chelidonine alkaloid ingredient reduces cadmium-induced nephrotoxicity in rats. *Journal of Natural Medicine* 2013; 67(1):159-167.
 62. Karamova NS, Fatykhova DG, Abdrakhimova YR,

- Il'inskaya ON. An investigation of antigenotoxic properties of plant extracts of *Chelidonium majus* L., *Plantago major* L. and *Tussilago farfara* L. Russian Journal of Genetics Applied Research 2011; 1(5):371-378.
63. Moussa SZ, El-Meadawy SA, Ahmed HA, Refat M. Efficacy of *Chelidonium majus* and propolis against cytotoxicity induced by chlorhexidine in rats. Egyptian Journal of Biochemistry and Molecular Biology 2007; 25:42-61.
 64. Kaminskyy VO, Lootsik MD, Stoika RS. Correlation of the cytotoxic activity of four different alkaloids, from *Chelidonium majus* (greater celandine), with their DNA intercalating properties and ability to induce breaks in the DNA of NK/Ly murine lymphoma cells. Central European Journal of Biology 2006; 1(1):2-15.
 65. Philchenkov A, Kaminskyy V, Zavelevich M, Stoika R. Apoptogenic activity of two benzophenanthridine alkaloids from *Chelidonium majus* L. does not correlate with their DNA damaging effects. Toxicology In Vitro 2008; 22(2):287-295.
 66. El-Readi MZ, Eid S, Ashour ML, Tahrani A, Wink M. Modulation of multidrug resistance in cancer cells by chelidonine and *Chelidonium majus* alkaloids. Phytomedicine 2013; 20(3-4):282-294.
 67. Colombo ML, Bugatti C, Mossa A, Pescalli N, Piazzoni L, Pezzoni G *et al.* Cytotoxicity evaluation of natural coptisine and synthesis of coptisine from berberine. Farmaco 2001; 56(5-7):403-409.
 68. Staniszewski A, Slesak B, Kolodziej J, Harłozinska-Szmyrka A, Nowicky JW. Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid alkaloid derivatives from *Chelidonium majus* L. (Ukraine). Drugs under Experimental and Clinical Research 1992; 18:63-67.
 69. Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K *et al.* NSC-631570 (Ukraine) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbecks Archives of Surgery 2002; 386(8):570-574.
 70. Uglyanitsa KN, Nechiporenko NA, Nefyodov LI, Doroshenko YM, Brzosko W, Nowicky W. Results of Ukraine monotherapy of prostate cancer. Drugs under Experimental and Clinical Research 2000; 26(5-6):191-193.
 71. Kadan P, Korsh OB, Melnyk A. Ukraine therapy of recurrent breast cancer with lung metastases (case report). Drugs under Experimental and Clinical Research 1996; 22(3-5):243-245.
 72. Nefyodov LI, Uglyanitsa KN, Nechiporenko NA, Smirnov VY, Brzosko W, Karavay NL. New biochemical mechanisms of the anticancer effect of Ukraine in the treatment of cancer of the urinary bladder. Drugs under Experimental and Clinical Research 2000; 26(5-6):195-199.
 73. Boegge SC, Kesper S, Verspohl EJ, Nahrstedt A. Reduction of ACh-induced contraction of rat isolated ileum by coptisine, (+)-caffeoylmalic acid, *Chelidonium majus* and *Corydalis lutea* extracts. Planta Medica 1996; 62(2):173-174.
 74. Hiller KO, Ghorbani M, Schilcher H. Antispasmodic and relaxant activity of chelidonine, protopine, coptisine, and *Chelidonium majus* extracts on isolated guinea-pig ileum. Planta Medica 1998; 64(8):758-760.
 75. Paul A, Das S, Das J, Samadder A, Khuda-Bukhs AR. Cytotoxicity and apoptotic signalling cascade induced by chelidonine-loaded PLGA nanoparticles in HepG2 cells *in vitro* and bioavailability of nano-chelidonine in mice *in vivo*. Toxicology Letters 2013; 222(1):10-22.
 76. Pencikova K, Kollar P, Muller Zavalova V, Taborska E, Urbanova J, Hosek J. Investigation of sanguinarine and chelerythrine effects on LPS-induced inflammatory gene expression in THP-1 cell line. Phytomedicine 2012; 19(10):890-895.
 77. Li W, Fan T, Zhang Y, Niu X, Xing W. Effect of chelerythrine against endotoxic shock in mice and its modulation of inflammatory mediators in peritoneal macrophages through the modulation of mitogen-activated protein kinase (MAPK) pathway. Inflammation 2012; 35(6):1814-1824.
 78. Brunhofer G, Fallarero A, Karlsson D, Batista-Gonzalez A, Shinde P, Gopi Mohan C *et al.* Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine. Bioorganic & Medicinal Chemistry 2012; 20(22):6669-6679.
 79. Cheng RB, Chen X, Liu SJ, Zhang GH. Effect of Chelerythrine on glucosyltransferase and water-insoluble glucan of *Streptococcus mutans*. Shanghai Journal of Stomatology 2007; 16(3):324-327.
 80. Parlakpınar H, Tasdemir S, Polat A, Bay-Karabulut A, Vardi N, Ucar M *et al.* Protective effect of chelerythrine on gentamicin-induced nephrotoxicity. Cell Biochemistry & Function 2006; 24(1):41-48.
 81. Liang J, Zeng F, Guo A, Liu L, Guo N, Li L *et al.* Microarray analysis of the chelerythrine-induced transcriptome of *Mycobacterium tuberculosis*. Current Microbiology 2011; 62(4):1200-1208.
 82. Li WF, Hao DJ, Fan T, Huang HM, Yao H, Niu XF. Protective effect of chelerythrine against ethanol-induced gastric ulcer in mice. Chemico-Biological Interactions 2014; 208:18-27.
 83. Ko FN, Chen IS, Wu SJ, Lee LG, Haung TF, Teng CM. Antiplatelet effects of chelerythrine chloride isolated from *Zanthoxylum simulans*. Biochimica et Biophysica Acta 1990; 1052(3):360-365.
 84. Vrba J, Dolezel P, Vicar J, Modriansky M, Ulrichova J. Chelerythrine and dihydrochelerythrine induce G1 phase arrest and bimodal cell death in human leukemia HL-60 cells. Toxicology *in vitro* 2008; 22(4):1008-1017.
 85. Feng G, Zhang J, Liu YQ. Inhibitory activity of dihydrosanguinarine and dihydrochelerythrine against phytopathogenic fungi. Natural Product Research 2011; 25(11):1082-1089.
 86. Schmeller T, Latz-Brüning B, Wink M. Biochemical activities of berberine, palmatine and sanguinarine mediating chemical defence against microorganisms and herbivores. Phytochemistry 1997; 44(2):257-266.
 87. Beuria TK, Santra MK, Panda D. Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling. Biochemistry 2005; 44(50):16584-16593.
 88. Adhami VM, Aziz MH, Mukhtar H, Ahmad N. Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clinical Cancer Research 2003; 9(8):3176-3182.
 89. Ahsan H, Reagan-Shaw S, Breur J, Ahmad N. Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in

- Bcl-2 family proteins. *Cancer Letters* 2007; 249(2):198-208.
90. Vrba J, Dolezel P, Vicar J, Ulrichova J. Cytotoxic activity of sanguinarine and dihydrosanguinarine in human promyelocytic leukemia HL-60 cells. *Toxicology in Vitro* 2009; 23(4):580-588.
 91. Niu X, Fan T, Li W, Huang H, Zhang Y, Xing W. Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice. *Toxicology and Applied Pharmacology* 2013; 267(3):256-265.
 92. Jeng JH, Wu HL, Lin BR, Lan WH, Chang HH, Ho YS *et al.* Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production. *Atherosclerosis* 2007; 191(2):250-258.
 93. Agarwal S, Reynolds MA, Pou S, Peterson DE, Charon JA, Suzuki JB. The effect of sanguinarine on human peripheral blood neutrophil viability and functions. *Oral Microbiology and Immunology* 1991; 6(1):51-61.
 94. Hattori T, Furuta K, Nagao T, Nagamatsu T, Ito M, Suzuki Y. Studies on the antinephritic effect of plant components (4): Reduction of protein excretion by berberine and coptisine in rats with original-type anti-GBM nephritis. *Japanese Journal of Pharmacology* 1992; 59(2):159-169.
 95. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H. Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. *Journal of Ethnopharmacology* 1999; 66(2):227-233.
 96. Cernakova M, Kost'aloova D, Kettmann V, Plodova M, Toth J, Drimal J. Potential antimutagenic activity of berberine, a constituent of *Mahonia aquifolium*. *BMC Complementary and Alternative Medicine* 2002; 2:1-6.
 97. Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA, Das BC. Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. *Molecular Cancer* 2011; 10:1-14.
 98. Hamsa TP, Kuttan G. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. *Drug and Chemical Toxicology* 2012; 35(1):57-70.
 99. Chang W, Zhang M, Li J, Meng Z, Xiao D, Wei S *et al.* Berberine attenuates ischemia-reperfusion injury via regulation of adenosine-5'-monophosphate kinase activity in both non-ischemic and ischemic areas of the rat heart. *Cardiovascular Drugs and Therapy* 2012; 26(6):467-478.
 100. Cok A, Plaisier C, Salie MJ, Oram DS, Cheng J, Louters LL. Berberine acutely activates the glucose transport activity of GLUT1. *Biochimie* 2011; 93(7):1187-1192.
 101. Domitrovic R, Jakovac H, Blagojevic G. Hepatoprotective activity of berberine is mediated by inhibition of TNF- α , COX-2, and iNOS expression in CCl(4)-intoxicated mice. *Toxicology* 2011; 280(1-2):33-43.
 102. Hayashi K, Minoda K, Nagaoka Y, Hayashi T, Uesato S. Antiviral activity of berberine and related compounds against human cytomegalovirus. *Bioorganic & Medicinal Chemistry Letters* 2007; 17(6):1562-1564.
 103. Peng WH, Wu CR, Chen CS, Chen CF, Leu ZC, Hsieh MT. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors. *Life Science* 2004; 75(20):2451-2462.
 104. Xiao X, Liu J, Hu J, Zhu X, Yang H, Wang C *et al.* Protective effects of protopine on hydrogen peroxide-induced oxidative injury of PC12 cells via Ca(2+) antagonism and antioxidant mechanisms. *European Journal Pharmacology* 2008; 591(1-3):21-27.
 105. Wei HL, Liu GT. Protective action of corynoline, acetylorynoline and protopine against experimental liver injury in mice. *Acta Pharmaceutica Sinica* 1997; 32(5):331-336.
 106. Ko FN, Wu TS, Lu ST, Wu YC, Huang TF, Teng CM. Antiplatelet effects of protopine isolated from *Corydalis tubers*. *Thrombosis Research* 1989; 56(2):289-298.
 107. Xu Q, Jin RL, Wu YY. Opioid, calcium, and adrenergic receptor involvement in protopine analgesia. *Acta Pharmacologica Sinica* 1993; 14:495-500.
 108. Bae DS, Kim YH, Pan CH, Nho CW, Samdan J, Yansan J *et al.* Protopine reduces the inflammatory activity of lipopolysaccharide-stimulated murine macrophages. *BMB Reports* 2012; 45(2):108-1013.
 109. Chen CH, Liao CH, Chang YL, Guh JH, Pan SL, Teng CM. Protopine, a novel microtubule-stabilizing agent, causes mitotic arrest and apoptotic cell death in human hormone-refractory prostate cancer cell lines. *Cancer Letters* 2012; 315(1):1-11.
 110. Huang YH, Zhang ZZ, Jiang JX. Relaxant effects of protopine on smooth muscles. *Acta Pharmacologica Sinica* 1991; 12(1):16-9.
 111. Kim SR, Hwang SY, Jang YP, Park MJ, Markelonis GJ, Oh TH *et al.* Protopine from *Corydalis ternata* has anticholinesterase and anti-amnesic activities. *Planta Medica* 1999; 65(3):218-221.
 112. Abu-Ghalyun Y, Masalmeh A, Al-Khalil S. Effects of allocryptopine, an alkaloid isolated from *Glauicum arabicum* on rat isolated ileum and urinary bladder. *General Pharmacology* 1997; 29(4):621-623.
 113. Li Y, Wang S, Liu Y, Li Z, Yang X, Wang H *et al.* Effect of alpha-allocryptopine on transient outward potassium current in rabbit ventricular myocytes. *Cardiology* 2008; 111(4):229-236.
 114. Gong LL, Fang LH, Qin HL, Lv Y, Du GH. Analysis of the mechanisms underlying the Vasorelaxant action of coptisine in rat aortic rings. *The American Journal of Chinese Medicine* 2012; 40(2):309-320.
 115. Guo J, Wang SB, Yuan TY, Wu YJ, Yan Y, Li L *et al.* Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflammation. *Atherosclerosis* 2013; 231(2):384-391.
 116. Shin HJ, Kim HL, Kim SJ, Chung WS, Kim SS, Um JY. Inhibitory effects of chelidonic acid on IL-6 production by blocking NF-kappaB and caspase-1 in HMC-1 cells. *Immunopharmacology and Immunotoxicology* 2011; 33(4):614-619.
 117. Oh HA, Kim HM, Jeong HJ. Beneficial effects of chelidonic acid on a model of allergic rhinitis. *International Immunopharmacology* 2011; 11(1):39-45.
 118. Bouquet J, Rivaud M, Chevalley S, Deharo E, Jullian V, Valentin A. Biological activities of nitidine, a potential anti-malarial lead compound. *Malaria Journal* 2012; 11:1-8.
 119. Chen J, Wang J, Lin L, He L, Wu Y, Zhang L *et al.* Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. *Molecular Cancer Therapeutics* 2012; 11(2):277-287.

120. Sun M, Zhang N, Wang X, Cai C, Cun J, Li Y *et al.* Nitidine chloride induces apoptosis, cell cycle arrest, and synergistic cytotoxicity with doxorubicin in breast cancer cells. *Tumour Biology* 2014; 35(10):10201-10212
121. Wang Z, Jiang W, Zhang Z, Qian M, Du B. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kappaB pathway in RAW 264.7 cells. *Journal of Ethnopharmacology* 2012; 144(1):145-150.
122. Iwasaki H, Oku H, Takara R, Miyahira H, Hanashiro K, Yoshida Y *et al.* The tumor specific cytotoxicity of dihydronitidine from *Toddalia asiatica* Lam. *Cancer Chemotherapy and Pharmacology* 2006; 58(4):451-459.
123. Pugsley MK, Saint DA, Hayes E, Berlin KD, Walker MJ. The cardiac electrophysiological effects of sparteine and its analogue BRB-I-28 in the rat. *European Journal of Pharmacology* 1995; 294(1):319-327.
124. Liu J, Zhang Q, Ye Y, Li W, Qiu J, Liu J *et al.* Angoline: a selective IL-6/STAT3 signalling pathway inhibitor isolated from *Zanthoxylum nitidum*. *Phytomedicine* 2014; 21(8-9):1088-1091.
125. Im SG, Yoo SH, Jeon DO, Cho HJ, Choi JY, Paik S *et al.* *Chelidonium majus*-induced acute hepatitis. *The Ewha Medical Journal* 2014; 37(1):60-63.
126. Moro PA, Casseti F, Giugliano G, Falce MT, Mazzanti G, Menniti-Ippolito F *et al.* Hepatitis from greater celandine (*Chelidonium majus* L.): review of literature and report of a new case. *Journal of Ethnopharmacology* 2009; 124(2):328-332.
127. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Greater celandine hepatotoxicity: a clinical review. *Annals of Hepatology* 2012; 11(6):838-848.
128. Barreto MC, Pinto RE, Arrabaca JD, Pavao ML. Inhibition of mouse liver respiration by *Chelidonium majus* isoquinoline alkaloids. *Toxicology Letters* 2003; 146(1):37-47.
129. Gohil KJ, Patel JA. Herb-drug interactions: A review and study based on assessment of clinical case reports in literature. *Indian Journal of Pharmacology* 2007; 39(3):129-139.
130. Qi XY, Liang SC, Ge GB, Liu Y, Dong PP, Zhang JW *et al.* Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. *Food and Chemical Toxicology* 2013; 56:392-397.
131. Eruvaram NR, Das M. Phenotype of hepatic xenobiotic metabolizing enzymes and CYP450 isoforms of sanguinarine treated rats: effect of P450 inducers on its toxicity. *Toxicology Mechanisms and Methods* 2009; 19(8):510-517.
132. Zdarilova A, Vrzal R, Rypka M, Ulrichova J, Dvorak Z. Investigation of sanguinarine and chelerythrine effects on CYP1A1 expression and activity in human hepatoma cells. *Food and Chemical Toxicology* 2006; 44(2):242-9.
133. Guo Y, Pope C, Cheng X, Zhou H, Klaassen CD. Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. *Journal of Ethnopharmacology* 2011; 138(1):111-118.
134. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. *European Journal of Clinical Pharmacology* 2012; 68(2):213-217.
135. Lo SN, Chang YP, Tsai KC, Chang CY, Wu TS, Ueng YF. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. *Toxicology and Applied Pharmacology* 2013; 272(3):671-680.
136. Salminen KA, Meyer A, Jerabkova L, Korhonen LE, Rahnasto M, Juvonen RO *et al.* Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. *Phytomedicine* 2011; 18(6):533-538.
137. Gebhardt R. Antioxidative, antiproliferative and biochemical effects in HepG2 cells of a homeopathic remedy and its constituent plant tinctures tested separately or in combination. *Arzneimittel-Forschung* 2003; 53(12):823-830.
138. Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®)-a safe and effective standard in the treatment of functional gastrointestinal disorders. *Wiener medizinische Wochenschrift* 2013; 163(3-4):65-72.